First-generation versus second-generation antipsychotics in adults: comparative effectiveness.
Abou-Setta AM, Mousavi SS, Spooner C, Schouten JR, Pasichnyk D, Armijo-Olivo S, Beaith A, Seida JC, Dursun S, Newton AS, Hartling L
Record ID 32013000774
English
Authors' objectives:
To compare individual first-generation antipsychotics (FGAs) with individual second-generation antipsychotics (SGAs) in adults (18 to 64 years) with schizophrenia, schizophrenia-related psychoses, or bipolar disorder, with a focus on core illness symptoms, functional outcomes, health care system utilization, and adverse events.
Authors' recommendations:
Few differences of clinical importance for outcomes of effectiveness were found. Patient-important outcomes were rarely assessed. Data were sparse for the four key adverse events deemed a priori to be most clinically important.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://effectivehealthcare.ahrq.gov/ehc/products/146/1054/CER_63_Antipsychotics%20in%20Adults_08-20-121.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Comparative Effectiveness Research
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.